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Abstract: OBJECTIVES Interstitial lung disease (ILD) is a key prognostic factor in connective tissue
disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in
various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective
tissue disorder (MCTD), following the use of rituximab therapy. METHODS A multicentre retrospective
analysis of patients with ILD secondary to SYN (n=15), MCTD (n=6) and SSc (n=23). PFTs were
performed at baseline and at 1 and 2 years of follow-up. The primary outcome was the change in forced
vital capacity (FVC) at 1 year. RESULTS In the SYN population, median FVC changed from 53.0%
(42.0-90.0) at baseline to 51.4% (45.6-85.0) at 1 year and 63.0 (50-88) (p=0.6) at 2 years (p=0.14).
In SSc, FVC changed from 81.0% (66.0-104.0) at baseline to 89.0% (65.0-113.0) at 1 year (p=0.1) and
74.5 (50-91) at 2 years (p=0.07). In the MCTD population, FVC changed from 64.5% (63.0-68.0) at
baseline to 63.0% (59.0-71.0) at 1 year (p=0.6) and 61 (59-71) after 2 years (p=0.8). DLCO showed a
trend for improvement in the SYN population (p=0.06 at 1 year and 0.2 at years) while changes remain
non-significant in the SSc and MCTD patients. In SYN patients, the percentage of responders at 1 year
for FVC (33.3%) was greater than in SSc (9.5%) (p=0.07) and MCTD (17%) (p=0.45). RTX showed
a satisfactory safety profile. CONCLUSIONS A trend of improvement of PFTs was observed in SYN
patients although not reaching significance, while SSc and MCTD patients were stabilised.
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ABSTRACT
Objective. Interstitial lung disease 
(ILD) is a key prognostic factor in 
connective tissue disorders (CTDs). 
The aim of our study was to assess the 
changes in pulmonary functional tests 
(PFTs) in various CTDs, including an-
ti-synthetase syndrome (SYN), systemic 
sclerosis (SSc) and mixed connective 
tissue disorder (MCTD), following the 
use of rituximab therapy.
Methods. A multicentre retrospective 
analysis of patients with ILD secondary 
to SYN (n=15), MCTD (n=6) and SSc 
(n=23). PFTs were performed at base-
line and at 1 and 2 years of follow-up. 
The primary outcome was the change in 
forced vital capacity (FVC) at 1 year.
Results. In the SYN population, me-
dian FVC changed from 53.0% (42.0-
90.0) at baseline to 51.4% (45.6-85.0) 
at 1 year and 63.0 (50-88) (p=0.6) at 2 
years (p=0.14). In SSc, FVC changed 
from 81.0% (66.0-104.0) at baseline to 
89.0% (65.0-113.0) at 1 year (p=0.1) 
and 74.5 (50-91) at 2 years (p=0.07). 
In the MCTD population, FVC changed 
from 64.5% (63.0-68.0) at baseline to 
63.0% (59.0-71.0) at 1 year (p=0.6) 
and 61 (59-71) after 2 years (p=0.8). 
DLCO showed a trend for improvement 
in the SYN population (p=0.06 at 1 year 
and 0.2 at years) while changes remain 
non-significant in the SSc and MCTD 
patients. In SYN patients, the percent-
age of responders at 1 year for FVC 
(33.3%) was greater than in SSc (9.5%) 
(p=0.07) and MCTD (17%) (p=0.45). 
RTX showed a satisfactory safety profile.
Conclusion. A trend of improvement of 
PFTs was observed in SYN patients al-
though not reaching significance, while 
SSc and MCTD patients were stabilised.
Introduction
Interstitial lung disease (ILD) is a com-
mon complication of various connec-
tive tissue diseases (CTD) including 
systemic sclerosis (SSc), mixed con-
nective tissue disease (MCTD) and 
anti-synthetase syndrome (SYN) (1, 2). 
In many cases, ILD dictates the prog-
nosis, as increased morbidity and mor-
tality are associated with ILD (3-5). 
ILD is clinically mainly characterised 
by a progressive dyspnoea. Pulmonary 
function tests (PFTs) is the first line tool 
showing restrictive ventilation defect 
with a reduction of vital capacity (VC) 
and of forced vital capacity (FVC) but 
without the reduction of forced expira-
tory volume in the first second (FEV1) 
as observed in obstructive defect. In 
addition in patients with ILD is often 
observed a reduced of diffusion capac-
ity for carbon monoxide (DLCO) (2, 
6). A recent study on SSc patients sug-
gested that a decline in PFTs represents 
a poor prognostic factor (7).
ILD is characterised by different histo-
pathological subsets. In SSc, the non-
specific interstitial pneumonia (NSIP) 
pattern may be found in up to 80% of 
patients (8). ILD is largely represented 
in MCTD by NSIP and less frequently 
by usual interstitial pneumonia (UIP) 
pattern (2). In SYN, more heterogeneous 
lesions may occur such as NSIP, usual 
interstitial pneumonia (UIP), cryptogen-
ic organising pneumonia (COP) and dif-
fuse alveolar damage (DAD) (2, 9).
Despite the high medical need, current-
ly available treatments remain limited 
and not established. In the last years, 
preliminary data have suggested that 
anti-CD20 rituximab (RTX) may be an 
effective treatment option for CTD-re-
lated ILD. Indeed in SSc, preliminary 
studies have suggested a stabilisation 
of pulmonary function test (PFTs) after 
a follow-up of 6 months and some im-
provement after 1 or 2 years of follow 
up (10-12). In SYN, available evidence 
is limited on case reports or small case 
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series (5, 13). In MCTD, the potential 
efficacy of RTX in ILD has not yet 
been studied.
The objective of our study was to eval-
uate the mid-term effects of RTX on 
lung function in ILD related to SYN, 
SSc and MCTD.
Materials and methods
SYN patients were characterised by the 
presence of anti-synthethase antibod-
ies. All SSc patients fulfilled the new 
ACR/EULAR classification criteria 
(14), MCTD patients had anti-RNP an-
tibodies and fulfilled at least one pro-
posed classification criteria (15). All 
enrolled patients presented ILD at chest 
high resolution computed tomography 
(HRCT) at baseline (ground-glass or 
reticular pattern or honey combing). 
Being a retrospective and multicentre 
study, lung involvement was not ho-
mogeneously followed up with HRCT 
according to different guidelines in 
these centres.
Enrolled patients were evaluated with 
LFTs at 1 year, and when available data 
concerning LFTs at 2 years of follow-
up were collected.
In addition to pulmonary assessment, 
other baseline parameters have been 
collected. For all SYN patients the 
presence of synovitis, myositis, in-
creased CPK levels (IU/l) and muscle 
weakness were recorded. In SSc popu-
lation the presence of synovitis, the 
last systolic pulmonary artery pressure 
(sPAP) and left ventricular fraction 
injection (LVEF) at the echocardiog-
raphy and the capillaroscopic pattern 
were recorded. MCTD patients were 
investigated for the presence of syno-
vitis and myositis.
Eight centres retrospectively collected 
data on SYN, SSc and MCTD patients 
treated with RTX used in routine care 
(see Table I for concomitant or previ-
ous therapy). Data regarding RTX ad-
ministration regimen, safety and use 
of methylprednisolone, DMARDs and/
or immunosuppressive treatment were 
also collected.
The primary outcome measure was 
the change in FVC assessed at 1 year. 
The secondary outcomes were DLCO 
values and the percentage of respond-
ers in PTF parameters. We first defined 
responders as patients with a ≥10% in-
crease in FVC and ≥15% increase of 
DLCO, as reported in recent randomised 
controlled trials evaluating treatment of 
idiopathic ILD (16). A second analysis 
was performed considering responders 
as patients with an increase of ≥5% of 
FVC and ≥10% of DLCO.
Statistical analysis
Data were analysed using the SAS 
System; non-parametric values are pre-
Table I. Clinical characteristics of three populations.
Parameters SSc (n=23) MCTD (n=6) SYN (n=15)
Age years (mean±sd) 58.8±10,42 50.83±6.1 50.5±15.16
Sex: Female n (%) 20 (86.9%) 5 (83.3%) 8 (67.7%)
Disease duration years (mean±sd) 7.96±7.65 8.91±8.45 6.66±6.16
Subset:   
diffuse cutaneous subset 18  
limited cutaneous subset 5  
Antibodies positivity n (%)   
ANA 23 (100%) 6 (100%) 8 (66.7%)
ACA 4 (17.4%)  
Anti-Scl70 13 (56.5%)  
Anti-RNA pol III 2 (8.7%)  
Anti-RNP  6 (100%) 
Anti-Jo1; ( or other anti-tRNA   15
synthetase) Anticardiolipine; Anti-SSA; Anti-SSB; AntiCCP; AntiRo; RF; 
Other Ab anti-PM/Scl; Anti-SSA;  Anti-PM/Scl; RF; Anti-CCP; SSA; Anti-TG
  Scl70 
Synovitis 9 (39.1%) 1 (16.7%) 6 (40%)
Myositis  1 (16.7%) 13 (86.7%)
Videocapillaroscopic pattern   
Early 7 (30.4%)  
Active 7 (30.4%)  
Late 9 (39.1%)  
Echocardiography   
sPAP>25 mmHg 16 (69.6%)  
LFEF≤40% 1 (4.4%)  
Dyspnoea n (%)   
NYHA 1 6 (26.7%) 2 (33.3) 2 (16.7%)
NYHA 2 11 (52.2%) 2 (33.3%) 2 (16.7%)
NYHA 3 3 (13%) 2 (33.3%) 2 (16.7%)
NYHA 4 1 (4.3%) 0 0
NYHA 3- NYHA 4 1 (4.3%) 0 0
DMARDs treatment during RTX therapy 15/23 (65.21%) 5/6 (83.3%) 8 (86.7%)
Previous or concomitant Cyclophosphamide 1/23 (4.3%) 1/6 (16.7%) 4/15 (26.7%)
SSc: systemic sclerosis; MCTD: mixed connective tissue disease; SYN: anti-synthetase syndrome; ANA: antinuclear antibodies; ACA: anticentromere 
antibodies; Anti-Scl70: antitopoisomerase I antibodies; anti-RNA pol III: anti-RNA polymerase III antibodies; anti-RNP: anti-ribonucleoprotein antibodies; 
anti-Jo1: anti –aminoacyl tRNA synthetase antibodies; DMARDs: disease modifying anti-rheumatic drugs.
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sented as median±interquartile range 
(IQR) and normally distributed data 
as mean±standard deviation (SD). 
Changes in PFTs parameters were ana-
lysed using the Wilcoxon Signed Rank 
Sum Test. The Fisher test was used to 
compare percentage of responders (a 
p-value <0.05 was considered statisti-
cally significant).
Results
Forty-four patients from 8 centres 
were enrolled: 15 with SYN, 23 with 
SSc and 6 with MCTD. Table I reports 
baseline characteristics. The detailed 
results for the change from baseline to 
1 or 2 years are shown in Table II and 
Figure 1.
For all the patients co-treatment with 
DMARDs or immunosuppressant was 
recorded. In SYN population, 8 patients 
received concomitant treatment with 
azathioprine (out of these subjects, two 
received prednisone, one methotrexate 
(MTX) and intravenous immunoglobu-
lin (IVIg), one cyclosporine and one 
IVIg). One patient was treated with 
prednisone and IVIg, one with pred-
nisone only and another one received 
concomitant treatment with MTX and 
cyclosporine. Still in SYN population, 
three patients were treated with cyclo-
phosphamide during the first and third 
RTX infusions. In SSc population, 9 
patients were treated with MTX (out 
of these 9 subjects, one also received 
mycophenolate mofetil (MMF)). One 
patient was treated with cyclophospha-
mide and oral prednisone, two patients 
with MMF and two with azathioprine. 
One patient received oral prednisone. 
In MCTD, two patients received con-
comitant treatment with cyclophospha-
mide (one only during the first year, 
during the second year he received 
MMF); two patients received MTX and 
one azathioprine.
The cumulative mean dose of RTX did 
not significantly differ between patients 
with SYN (2.170 gr at 1 year, 1.910 
gr at 2 years), SSc (2.800 gr at 1 year, 
1.750 gr at 2 years) and MCTD (1.900 
gr at 1 year, 1.400 gr at 2 years). All pa-
tients received premedication with ster-
oid; in Table I, DMARDs and immuno-
suppressive co-treatment are shown.
When available, PFT values prior to 
RTX treatment were also recorded. 
SYN patients had already a reduced 
FVC value as compared to expected 
values, and they also exhibited a re-
cent decline before starting RTX ther-
apy (58 (48-82) to 53 (42-90)). In SSc 
population, although there was a prior 
decline in FVC values (from 88 (79-
102) to 81 (66-104)), it is of note that 
the median value remained weakly al-
tered. In the MCTD group of patients, 
no prior decline in FVC values was ob-
served although the decision of the cli-
nicians was driven by a recent decrease 
in DLCO (23 (40- 61) to 41 (30-46)).
Primary outcome measure
In the SYN population, median FVC 
changed from 53.0% (42.0-90.0) at 
baseline to 51.4% (45.6- 85.0) at 1 year 
(p=0.59) and a trend of improvement 
was observed at 2 years (63.0 (50-88), 
p=0.1).
In SSc population an increase of FVC 
from baseline to 1 year value was ob-
served (81.0% (66.0-104.0) to 89.0% 
(65.0-113.0); p=0.1), on the contrary it 
showed a decrease at 2 years of follow-
up (74.5 (50-91); p=0.07).
In the MCTD population, FVC was 
stable from the baseline to the 1 year of 
follow-up (from 64.5% (63.0-68.0) to 
63.0% (59.0-71.0), p=0.6) and a mini-
mal decrease was stable after 2 years 
(61 (59-71), p=0.8).
Secondary outcome measures
In SYN, an increase of DLCO close to 
significance was observed from base-
line to 1 year (41.7 (31.1-61) to 52 
(34.9-65), p=0.06) and a stabilisation 
of this value was observed at 2 years of 
follow up (51.8 (34-63.4), p=0.2.
In patients with SSc, DLCO was stable 
from baseline to 2 years of follow-up 
(54 (39-67.8 to 57.5 (38.5-70.5) and a 
trend of improvement at 1 year (61 (47-
64), p=0.6).
In MCTD group, a stabilisation of 
DLCO was observed from baseline to 
1 year (41 (30-46) to 38 (34- 49), p= 
0.8) and it showed a trend in improve-
Table II. PFTs follow up.
 PFTs parameters Prior-RTX Baseline 1 Year p-value 2 Years p-value
     (baseline-  (baseline-
     1 year)   2 years)
SYN FVC median (IQR) % (n) 58 (48-82) 11 53 (42-90) 15 51.4 (45,6-85) 15 0.59 63.05 (50-88) 6 0.14
 TLC median (IQR) % (n) 74 (53-88) 6 60.8 (49-84) 11 66 (55.6-88) 9 0.48 58 (54-81) 4 0.1
 DLCO median (IQR) % (n) 52 (33-79) 7 41.7 (31.10-61) 12 52 (34.9-65) 11 0.059 51.85 (34-63.4) 5 0.20
 DLCO/AVmedian (IQR) % (n) 72.7 (51-95) 6 76 (69-83) 11 73 (64-93.3) 10 0.83 82.5 (33-86) 5 0.89
SSc FVCmedian (IQR)% (n) 88 (79–102) 18 81 (66-104) 23 89 (65-113) 21 0.98 74.5 (50–91) 10 0.066
 TLC median (IQR) %(n) 94 (82-109.5) 16 85 (77-99) 21 90,5 (72.5-103.45) 20 0.51 77 (59-105) 7 0.40
 DLCO median (IQR)% (n) 62.5 (55-68) 18 54 (39-67.8) 23 61 (47-64) 19 0.62 57.5 (38.5-70.5) 8 0.89
 DLCO/AV median (IQR)% (n) 73 (69.5-92) 15 79.1 (61-87) 21 76 (64.2-82) 15 0.53 74.5 (66-88) 6 0.75
MCTD FVC median (IQR) % (n) 59 (50-75) 3 64.5 (63-68) 6 63 (59-71) 5 0.58 61 (59-71) 5 0.78
 TLC median (IQR) % (n) 74 (59-80) 3 69 (68-72) 5 68 (68-91) 4 1.00 72 (69-73) 5 0.58
 DLCO median (IQR) % (n) 53 (40-61) 3 41 (30-46) 6 38 (34-49) 5 0.88 47 (46-51) 5 0.36
 DLCO/AVmedian (IQR) % (n) 94 (84-96) 3 75 (59-88) 6 67 (64-69) 5 1.00 82 (55-94) 5 0.58
FVC: forced vital capacity; DLCO: diffusing capacity for carbon monoxide; TLC: total lung capacity; DLCO/AV: DLCO corrected for alveolar volume; 
Prior-RTX: evaluation about 12 months before the baseline; Baseline: time 0= beginning of RTX therapy; 1 year: evaluation 1 year after the baseline; 2 
years: evaluation 2 years after the baseline; SSc: Systemic sclerosis; MCTD: Mixed connective tissue disease; SYN: Anti-synthetase syndrome; N.R.: Wil-
cox test non realisable for the small population. In the graph, FVC and DLCO values are expressed as median for each disease.
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ment at 2 years of follow-up (82 (55-
94), p=6).
As specified, the secondary outcome 
was also the percentage of respond-
ers in PFT parameters comparing the 
baseline value to the last available one. 
The percentage in FVC responders was 
greater in the SYN population than SSc 
(33.3% vs. 9.5%, p=0.071) and MCTD 
patients (33.3% vs. 16.7%, p=0.454). 
Conversely, the percentage of respond-
ers in DLCO, was similar in SYN and 
SSc populations (27.3% vs. 23.8%, 
p=0.830). Defining responders as pa-
tients with an increase in FVC≥5%, the 
SYN population confirmed to have a 
higher percentage of responders com-
pared to SSc patients (53.3% vs. 21.7%) 
(p=0.051).
RTX safety
In RTX-treated patients, the following 
serious adverse events were reported: 
cardiac involvement with arrhythmia 
(n=1), fatigue (n=3), infections requir-
ing antibiotic therapy in 6 patients 
(without hospitalisation) (n=6), se-
rum sickness requiring hospitalisation 
(n=2).
Discussion
Few preliminary studies suggested RTX 
efficacy on ILD in SSc and SYN at least 
in the short term (10-13). As far as we 
know, we herein report the first retro-
spective study investigating three CTDs 
and providing 1 or 2 years of follow-up.
The effects of RTX in the SYN popu-
lation were indeed encouraging in the 
present study showing a trend of im-
provement from baseline to 2 years 
of follow-up and an improvement of 
DLCO close to significance; in addition 
in SYN patients the highest percentage 
of FVC responders was observed.
Our preliminary data are consistent 
with the results of previous studies (13) 
showing a possible role of rituximab in 
patients with ILD-related to SYN and 
with the data indicating PFTs improve-
ment after a median follow-up of 52 
months (17). However, in our study, 
the trend of improvement of FVC and 
DLCO does not reach significance and 
a study with a larger population is re-
quested in order to confirm our data. 
In addition, RTX in SYN population 
could improve also the muscle involve-
ment leading to a greater expansion 
of the thoracic cage and contributing 
to the improvement in PFTs. For this 
reason, other studies focusing on the 
broader RTX effects in SYN popula-
tion are mandatory.
In SSc and in MCTD, our data are par-
tially in line to those of previous stud-
ies (12, 13). In SSc, FVC showed a sta-
ble value at 1 year and 2 years and can 
be interpreted as a “non-progression” 
of the disease and these data seem very 
similar with what has been obtained 
in SSc-ILD with cyclophosphamide 
with a stability of lung functions (18, 
19). In the study of Jordan et al. (10), 
showing a stability of FVC and a sig-
nificant improvement of DLCO, the 
SSc population presented evidence 
of ILD at HRCT and a mean disease 
duration similar to our patients. How-
ever, in this EUSTAR analysis (10), 
patients seemed to have a more se-
vere ILD involvement with baseline 
DLCO and FVC values <70%. These 
parameters may influence the response 
to RTX therapy: more severe patients 
may be more likely to respond. These 
observations might suggest the need of 
more homogenous population for fu-
ture studies. In addition, in our study, 
SSc patients had a higher baseline 
FVC value when compared to the SYN 
population which may partially explain 
the higher percentage of responders in 
SYN compared to SSc. Indeed, SYN 
patients presenting with a lower FVC 
value may have a greater margin for 
improvement. To our knowledge, this 
is the first study on the role of RTX in 
ILD MCTD patients where a potential 
role for RTX in stabilisation of lung in-
volvement is suggested.
RTX was well tolerated with an accept-
able safety profile, consistent with the 
safety data reported in other rheumatic 
autoimmune diseases (10).
Our retrospective study presents some 
limitations, including, a limited sam-
ple size (although reflecting the rar-
ity of these diseases) and the different 
administration scheme of RTX among 
centres. However, in previous studies 
demonstrating the efficacy of RTX in 
pulmonary disease, different schemes 
of administration have been used (11, 
18) without significant differences in 
the clinical outcomes. This evidence 
highlight the need to analyse the bet-
ter dosing of RTX in controlled study 
in order to confirm its potential role to 
control SSc lung involvement and to 
verify with a meta-analysis the pos-
sible different outcomes based on the 
administration regimen.
Another limitation of our study was 
the fact that some patients received 
DMARDs and/or immunosuppressive 
treatment concurrently to RTX and 
they may have influenced the effects of 
RTX.
Fig. 1. FVC and DLCO follow-up.
FVC: forced vital capacity; DLCO: diffusing capacity for carbon monoxide; Ante-RTX: evaluation 
about 12 months before the baseline; Baseline: time 0= beginning of RTX therapy; 1 year: evaluation 1 
year after the baseline; 2 years: evaluation 2 years after the baseline; SSc: Systemic sclerosis; MCTD: 
Mixed connective tissue disease; SYN: Anti-synthetase syndrome. In the graph, FVC and DLCO val-
ues are expressed as median  for each disease.
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In conclusion, this study indicates that 
RTX in CTDs may help to control the 
course of ILD, representing a promis-
ing treatment of SYN-related ILD and 
producing a stabilisation of lung in-
volvement in SSc and MCTD. Indeed, 
immunosuppression, despite not being 
able to reverse fibrotic changes, may 
help in slowing disease progression. In 
the future, randomised controlled trials 
should clarify whether RTX treatment 
may help to counteract the evolution 
of ILD, a critical prognostic factors in 
these diseases.
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